Compare Abeona Therapeutics Inc (ABEO) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs MPLX LP — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while MPLX LP trades at $59.68 (market cap $60.12B). The key difference: MPLX LP is far larger — about 142.7× Abeona Therapeutics Inc's market cap, and MPLX LP pays a 7.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MPLX | |
|---|---|---|
Market Cap | $421.19M | $60.12B |
Sector | Health | Technology |
52-Week High | $7.45 | $60.51 |
52-Week Low | $4.17 | $47.80 |
Enterprise Value | $276.10M | $85.22B |
Dividend Yield | — | 7.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
MPLX trades at $59.76, up 1.81% with a bullish technical outlook. The stock shows strong profitability with a 40.45% net income margin and a P/E of 12.75. Recent Q2 2026 earnings missed expectations, but revenue grew to $11.7B in 2026. The company announced a $2.25 billion senior notes offering on August 10, 2026, to fund growth projects, supporting its fee-based infrastructure model.
Outlook is positive with a consensus price target of $61.50, though risks include rising capital spending and leverage. The dividend yield remains attractive, with a $1.08 distribution declared for H2-2026. Investors should weigh solid cash flow against execution risks in expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
